Aromatase inhibitors are most beneficial for postmenopausal women with ER+ breast cancer. They are less commonly used in premenopausal women because their ovaries still produce significant amounts of estrogen, which these drugs do not effectively block. In some cases, aromatase inhibitors may also be used in men with hormone-receptor-positive cancers.
